The Filing Desk

Novocure vs TransMedics Group

Novocure NVCR · TransMedics Group TMDX · Health Care Equipment

Novocure reported revenue of $655 million in fiscal 2025, about the same as TransMedics Group's $606 million in fiscal 2025. Novocure's revenue grew 8.3% in its latest year, and TransMedics Group's grew 37.1%. Novocure had an operating margin of -23.5%, against 17.9% at TransMedics Group. Free cash flow was −$76 million at Novocure and $134 million at TransMedics Group.

Side by side

NovocureTransMedics Group
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$655M$606M
Revenue growth8.3%37.1%
Revenue growth a year, last 5 years5.8%88.3%
Gross margin74.5%59.9%
Operating margin−23.5%17.9%
Net margin−20.8%31.4%
Free cash flow−$76M$134M
Free cash flow margin−11.6%22.1%
Return on capital−33.0%27.5%
Net debt to EBITDA—−0.2x
Dividends and buybacks$0M$0M
Change in diluted share count3.4%15.1%
Last close$11.83$91.38
P/E at the last close—25.0×
Insider trades, last 12 monthssold $2.9 millionbought $1.1 million, sold $4.7 million
Piotroski F-score4 of 97 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NovocureTransMedics Group
Operating margin
Percent of revenue
NovocureTransMedics Group
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NovocureTransMedics Group

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Novocure and TransMedics Group pages.